Products

Bracco’s commitment to diagnostic imaging began in the 1950’s and obtained the first results at the start of the 1960’s, with the development of the first contrast agent to improve image quality in radiographic procedures: iodamide.

Iopamidol: a revolutionary molecule

The following years saw a redoubling of efforts in R&D, and resulted in the development of a highly innovative contrast agent, iopamidol, which allowed for dramatically improved tolerability and safety during radiographic, vascular and CT procedures. Launched at the beginning of the 1980’s, it is still today the go-to product for the entire international scientific community.

Constant commitment to research

Other significant Bracco research achievements include the development of

  • a contrast medium for MRI procedures based on gadobenate dimeglumine, introduced in 1998,
  • a contrast agent for ultrasound examinations based on microbubble with sulfur hexafluoride gas, made available in 2001.

Both of these products represented a significant step forward in terms of what was available on the market at the time.

Medical device

The Bracco diagnostic imaging product portfolio is completed by several medical devices and advanced administration systems for contrast imaging products in the fields of cardiology and radiology, developed by Acist Medical Systems. The company, which was acquired by the Bracco Group in 2001, has its corporate headquarters, manufacturing and R&D facilities in Minneapolis, Minnesota (USA), with regional offices in Europe and Asia. Its advanced systems are used in over 40 countries in the most world-renowned centres. More than 15 million people around the world have had cardiovascular angiographic procedures using an ACIST system.

Later, Bracco’s product portfolio was further enhanced by other contrast agents for CT scans, MRI and by medical devices to optimize the administration of contrast media in different imaging modalities.

Surgvision and Blue Earth Diagnostics: the latest acquisitions

In October, 2017 Bracco acquired SurgVision, a high-tech innovative start-up company specialized in developing a real-time Fluorescence Image Guided Surgery platform combining a targeted imaging agent and a device for efficient tumor visualization during oncology surgical procedures.

In 2019 Bracco Imaging also enriched its product portfolio by expanding the range of oncology nuclear imaging solutions in the urology segment and other specialties with the acquisition of Blue Earth Diagnostics. The company is active in molecular imaging with innovative agents for positron emission tomography (PET) in patients with suspected recurrent prostate cancer.

Healthcare services

Another important area of activity for the Bracco Group regards the healthcare services provided by the Italian Diagnostics Centre, a polyclinic based in Milan. With 24 satellite units in the city and in Lombardy, the CDI offers different services of prevention, diagnosis, rehabilitation and personalized treatment, with a focus on radiosurgery and day-surgery.

Diagnostic Imaging

Diagnostic Imaging

Bracco Imaging is an international leader in diagnostic imaging.

Diagnostic Imaging

Read more

Acist Medical Systems

Acist Medical Systems

ACIST® Medical Systems is a market leader in advanced contrast imaging systems for cardiovascular angiography.

Acist Medical Systems

Visit the site


Healthcare Services

Healthcare Services

Bracco CDI is a medical surgery oriented to prevention, diagnosis and treatment.


Healthcare Services

Read more